.. Farmacovigilancia-para-las-américas, 61 3.1.2, p.62

H. Ops-et-l-'oms and .. , 72 5.1. Collaboration avec la Dirección General de Drogas y Farmacias (DGDF) 73 5.2. Collaboration avec l, p.73

D. La, Annexe 29 ? Formulaire de notification d'EI et son guide remis à, p.131

R. 1. Molière, Acte III, Scène 3. La Malade Imaginaire. 1673. 2. Regard historique sue la mise en place de la première vigilance française: la pharmacovigilance, Académie des Sciences et Lettres de, 2010.

F. L. Trépardoux, arrêt du conseil d'Etat du roi du 17 mars 1731, instituant la commission des remèdes spécifiques, Rev Hist Pharm, vol.44, pp.368-377, 0312.

W. Mcbride, Thalidomide and congenital abnormalities, Lancet, vol.2, p.1358, 1961.

A. Herbst, Adenocarcinoma of the Vagina, New England Journal of Medicine, vol.284, issue.16, pp.878-81, 1971.
DOI : 10.1056/NEJM197104222841604

R. Kaufman, Upper genital tract changes associated with exposure in utero to diethylstilbestrol, American Journal of Obstetrics and Gynecology, vol.128, issue.1, pp.51-60, 1977.
DOI : 10.1016/0002-9378(77)90294-0

R. Kaufman, Upper genital tract changes and pregnancy outcome in offspring exposed in utero to diethylstilbestrol, American Journal of Obstetrics and Gynecology, vol.137, issue.3, pp.299-308, 1980.
DOI : 10.1016/0002-9378(80)90913-8

W. Gill, Paathological semen and anatomical abnormalities of the genital tract in human male subjects exposed to diethylstilbestrol in utero, J Urol, vol.117, pp.477-80, 1977.

M. Bibbo, Follow?up study of male and female offsprings of D.E.S. exposed mothers, Obst Gynecol, vol.49, pp.1-8, 1977.

O. Mondiale-de and L. Santé, Pharmacovigilance internationale: rôle des centres nationaux [Internet]. Genève Glossary of Terms used in Pharmacovigilance, 1972.

S. Español-de-farmacovigilancia, Buenas Prácticas de Farmacovigilancia del Sistema Español de Farmacovigilancia

O. Panamericana-de and L. Salud, Buenas Prácticas de Farmacovigilancia para las Américas [Internet]. Organizacion Panamericana de la Salud, Disponible sur, 2010.

A. Bensadon, E. Marie, and A. Morelle, Rapport sur la pharmacovigilance et gouvernance de la chaîne du médicament [Internet]. Inspection générale des affaires sociales; 2011 juin

I. Edward and J. Aronson, Adverse drug reactions: definitions, diagnosis, and management, The Lancet, vol.356, issue.9237, pp.1255-1264, 2000.
DOI : 10.1016/S0140-6736(00)02799-9

R. Article and . Internet, Code de la Santé Publique nov 10, Disponible sur, 2012.

M. Rawlins and J. Thompson, Pathogenesis of adverse drug reactions. Textbook of adverse drug reactions, 1977.

H. Medicines, R. Products, and . Agency, Adverse drug reactions [Internet]. 2014 [cité 15 juill 2014]. Disponible sur: http://www.mhra.gov.uk/Safetyinformation/Howwemonitorthesafetyofproducts, p.3

?. Farmacovigilancia, ?. Adversas, and . Notificaciones, Curso Libre de Farmacología II Guías de Práctica Clínica [Internet] Universidad Nacional de Córdoba Disponible sur: www.cfe?fcm.unc.edu.ar 26. Malgor?Valsecia. Farmacovigilancia y Mecanismo de reacciones adversas a medicamentos. Farmacologia medica, 2009.

J. Aronson, Drug therapy. Davidson's principles and practice of medecine. 19th éd, pp.147-63, 2002.

J. Aronson and R. Ferner, Joining the DoTS: new approach to classifying adverse drug reactions, BMJ, vol.327, issue.7425, pp.1222-1227, 2003.
DOI : 10.1136/bmj.327.7425.1222

P. Pouyanne, F. Haramburu, J. Imbs, and B. Bégaud, Admissions to hospital caused by adverse drug reactions: cross sectional incidence study, BMJ, vol.320, issue.7241, p.1036, 2000.
DOI : 10.1136/bmj.320.7241.1036

A. Philips, O. Nigro, and K. Scarborough, Hospital admissions caused by adverse drug events: an Australian prospective study, Australian Health Review, vol.38, issue.1, pp.51-58, 2014.
DOI : 10.1071/AH12027

P. Alvarez, F. Bril, V. Castro, I. Meiville, and C. Gonzalez, Adverse drug reactions as a reason for admission to an internal medicine ward in Argentina, Int J Risk Saf Med, vol.25, issue.3, pp.185-92, 2013.

M. Pirmohamed, S. James, S. Meakin, and C. Green, Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients, BMJ, vol.329, issue.7456, pp.15-24, 2004.
DOI : 10.1136/bmj.329.7456.15

A. Miguel, L. Azevedo, M. Araújo, and A. Pereira, Frequency of adverse drug reactions in hospitalized patients: a systematic review and meta-analysis, Pharmacoepidemiology and Drug Safety, vol.24, issue.5, pp.1139-54, 2012.
DOI : 10.1002/pds.3309

F. Haramburu, P. Pouyanne, J. Imbs, J. Blayac, and B. Bégaud, Incidence and prevalence of adverse drug reactions, Presse Med. janv, vol.29, issue.2, pp.111-115, 2000.

S. Taché, A. Sönnichsen, and D. Ashcroft, Prevalence of Adverse Drug Events in Ambulatory Care: A Systematic Review, Annals of Pharmacotherapy, vol.274, issue.7-8, pp.977-89, 2011.
DOI : 10.1001/jama.1995.03530010043033

J. Lazarou, B. Pomeranz, and P. Corey, Incidence of Adverse Drug Reactions in Hospitalized Patients, JAMA, vol.279, issue.15, pp.1200-1205, 1998.
DOI : 10.1001/jama.279.15.1200

M. Kvasz, I. Allen, M. Gordon, E. Ro, and R. Estok, Adverse drug reactions in hospitalized patients: A critique of a meta?analysis, MedGenMed. avr, vol.2, issue.2, 2000.

R. Rodríguez?monguió, O. Mj, and J. Rovira, Assessing the Economic Impact of Adverse Drug Effects, PharmacoEconomics, vol.19, issue.2, pp.623-50, 2003.
DOI : 10.2165/00019053-200321090-00002

H. Gyllensten, K. Hakkarainen, S. Hägg, A. Carlsten, and M. Petzold, Economic Impact of Adverse Drug Events ??? A Retrospective Population-Based Cohort Study of 4970 Adults, PLoS ONE, vol.14, issue.3, 2014.
DOI : 10.1371/journal.pone.0092061.t005

D. Rottenklober, J. Hasford, and J. Stausberg, Costs of Adverse Drug Events in German Hospitals???A Microcosting Study, Value in Health, vol.15, issue.6, pp.868-75, 2012.
DOI : 10.1016/j.jval.2012.05.007

P. Eftekhari, Organisation de la Pharmacovigilance. 2013 nov 8

B. Lebrun?vignes and . Organisation-de-la-pharmacovigilance-en-france-nov-;-crpv-groupe-hospitalier-pitié?salpêtrière, Disponible sur Disponible sur: http://www.ema.europa World Health Organisation. Being a member of the WHO Programme for International Drug Monitoring, Organisation_de_la_ph armacovigilance.pdf 49. European Medicines Agency. European Medicines Agency [Internet]. [cité 17 juill 2014] Que signifie être membre du Programme de l'OMS pour la pharmacovigilance internationale, 2010.

M. Lindquist and . Vigibase, the WHO Global ICSR Database System: Basic Facts, Drug Inf J, vol.42, pp.409-428, 2008.

S. Marks and . Medwatch, Safety Information and Adverse Event Reporting, Medscape Pharm, 2009.

J. González, V. Arango, and T. Einarson, Contribution of Latin America to Pharmacovigilance, Annals of Pharmacotherapy, vol.71, issue.1, pp.1394-1403, 2006.
DOI : 10.1345/aph.1H052

R. Benkirane, Détection des effets indésirables des médicaments en post AMM : Cours Francophone Inter pays de Pharmacovigilance

N. Sarkis, Organisation d'un système national de pharmacovigilance, Science Biologique et médicales]. Université Bordeaux, issue.2, 2006.

P. Psip-?, Patient Safety through Intelligent Procedures in Medication Success Story

E. Chazard, Prévention et détection des effets indésirables médicamenteux : le Projet européen PSIP, 2011.

A. European-medicines, Heads of Medicines Agencies. Guideline on good pharmacovigilance practices (GVP), 2012.

B. Bannwarth, Crit??res d???imputabilit?? des effets ind??sirables des m??dicaments, Revue du Rhumatisme Monographies, vol.77, issue.2, pp.173-178, 2010.
DOI : 10.1016/j.monrhu.2010.02.007

F. Haramburu, G. Miremont?salamé, and K. Macquin, Effets ind??sirables des m??dicaments??: d??finitions et imputabilit??, Revue du Rhumatisme, vol.69, issue.4, pp.346-354, 2002.
DOI : 10.1016/S1169-8330(02)00305-8

R. Hire, P. Kinage, and N. Gaikwad, Causality Assessment in Pharmacovigilance: A Step Towards Quality Care, Sch J App Med Sci, vol.1, issue.5, pp.386-92, 2013.

J. Dangoumeau, J. Evreux, and J. Joulard, Méthode d'imputabilité des effets indésirables des médicaments, Thérapie, vol.33, pp.373-81, 1978.

B. Begaud, J. Evreux, and J. Jouglard, Imputabilité des effets inattendus ou toxiques des médicaments Actualisation de la méthode utilisée en France, Thérapie, vol.40, pp.111-119, 1985.

C. A. Naranjo and U. Busto, A method for estimating the probability of adverse drug reactions, Clinical Pharmacology and Therapeutics, vol.30, issue.2, pp.239-284, 1981.
DOI : 10.1038/clpt.1981.154

A. Syed and . Zaki, Adverse drug reaction and causality assessment scales, Lung India. avr, vol.28, issue.2, pp.152-155, 2011.

H. Théophile, Y. Arimone, G. Miremont?salamé, N. Moore, A. Fourrier?réglat et al., Comparison of Three Methods (Consensual Expert Judgement, Algorithmic and Probabilistic Approaches) of Causality Assessment of Adverse Drug Reactions, Drug Safety, vol.77, issue.6, pp.1045-54, 2010.
DOI : 10.2165/11537780-000000000-00000

H. Théophile, M. André, G. Miremont?salamé, Y. Arimone, and B. Begaud, Comparison of Three Methods (An Updated Logistic Probabilistic Method, the Naranjo and Liverpool Algorithms) for the Evaluation of Routine Pharmacovigilance Case Reports Using Consensual Expert Judgement as Reference, Drug Safety, vol.28, issue.7, pp.1033-1077, 2013.
DOI : 10.1007/s40264-013-0083-1

N. Institue, P. Health, . Atc, and . Index, WHO Collaborating Centre for Drug Statistics Methodology, Disponible sur, 2014.

C. Uppsala-monitoring, WHO?ART guide [Internet] Disponible sur

L. Alj, R. Benkirane, and R. Soulaymani?bencheikh, WHO Adverse Reaction Terminology WHO?ART, Terminologie des Effets Indésirables : Cours Francophone Inter pays de Pharmacovigilance

O. Mondiale-de and L. Santé, Classification statistique internationale des maladies et des problèmes de santé connexes ? 10e révision [Internet] Disponible sur: http://apps.who.int/classifications, 2008.

P. Inc, What Is a Safety Signal ? [Internet] Disponible sur, 2011.

G. Chêne, M. Savès, A. Benard, and G. Coureau, Diplômes d'Université Méthodes et pratique en épidémiologie : Enseignement via Internet, 2013.

A. Bradford?hill, The environment and disease: assocation or causation?, Proc R Soc Med, vol.58, pp.295-300, 1965.

R. Soulaymani?bencheikh, C. Anti-poison, and . De-pharmacovigilance-du-maroc, Identification évaluation d'un signalement et déclenchement d'une alerte : Cours Francophone Inter pays de Pharmacovigilance

. Ministerio-de-economía, . Planificación, and . Desarrollo, Estimaciones de la pobreza monetaria y la desigualdad de ingresos familiares mediante la Encuesta de Fuerza de Trabajo (EFT) del Banco Central [Internet] Disponible sur: www.economia.gob.do 95, Programa de las Naciones Unidad para el Desarollo. Informe sobre Desarrollo Humano 2013 ? El ascenso del Sur: Progreso humano en un mundo diverso [Internet]. Communications Development Incorporated; 2013. Disponible sur, 2011.

M. Rathe and A. Moliné, Sistema de salud de República Dominicana, 2011.

H. Institute and E. Metrics, Disponible sur: http://www.healthdata.org/gbd 99, Disease (GBD) [Internet]. [cité 22 juill 2014, 2001.

L. Salmi, A. Puello, and J. Bhatti, Feasibility of a road trafic injury surveillance integrating police and health insurance datasets in the Dominican Republic. Inj Prev, pp.52-52, 2012.

E. Secretaría-de, Disponible sur: http://apps.who.int/medicinedocs/documents/s18241es/s18241es.pdf 109 AF Comunicación estratégica, 2005.

R. Alcántara, El 66% de inscritos el pasado semestre en UASD son mujeres

S. Resumen-de, Quiénes Somos [Internet]. Resumen de Salud, pp.2014-2026

B. Bégaud, J. Evreux, and J. Jouglard, Imputabilité des effets inattendus ou toxiques des médicaments Actualisation de la méthode utilisée en France R? : rechallenge négatif ; C3 : chronologie vraisemblable, C2 : chronologie plausible, C1 : chronologie douteuse, C0 : chronologie incompatible L+ : test de laboratoire positif, L0 : test de laboratoire non fait, L? : test de laboratoire négatif ; S3 : sémiologie vraisemblable, S2 : sémiologie plausible, S1 : sémiologie douteuse I4 : imputabilité très vraisemblable, I3 : imputabilité vraisemblable, I2 : imputabilité plausible, I1 : imputabilité douteuse, I0 : imputabilité incompatible Annexe 7 ? Situation géographique et carte de la République Dominicaine Tiré de Google Maps, disponible sur http, Source Therapie, vol.40, 1985.